The reimbursement process in three national healthcare systems: variation in time to reimbursement of pembrolizumab for metastatic non-small cell lung cancer

Sharman Moser, S. orcid.org/0000-0002-9745-2016, Tanser, F., Siegelmann-Danieli, N. et al. (3 more authors) (2023) The reimbursement process in three national healthcare systems: variation in time to reimbursement of pembrolizumab for metastatic non-small cell lung cancer. Journal of Pharmaceutical Policy and Practice, 16 (1). 22. ISSN 2052-3211

Abstract

Metadata

Item Type: Article
Authors/Creators:
Copyright, Publisher and Additional Information:

© 2025 The Authors. This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Keywords: Health policy; Lung cancer; Pembrolizumab; Reimbursement
Dates:
  • Published: 11 March 2023
  • Published (online): 11 March 2023
  • Accepted: 7 February 2023
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > Health Sciences School (Sheffield)
Depositing User: Symplectic Sheffield
Date Deposited: 23 Jan 2025 10:04
Last Modified: 23 Jan 2025 10:04
Published Version: https://doi.org/10.1186/s40545-023-00529-0
Status: Published
Publisher: Informa UK Limited
Refereed: Yes
Identification Number: 10.1186/s40545-023-00529-0
Related URLs:
Sustainable Development Goals:
  • Sustainable Development Goals: Goal 3: Good Health and Well-Being
Open Archives Initiative ID (OAI ID):

Export

Statistics